C9 and Parkinson disease: Human studies showed controversial results; some confirmed the involvement of the classical complement pathway by recognizing anti C3d, C4d, C7 and C9 antibodies in substantia nigra or by the aggregation of iC3b and C9 in Lewy bodies of PD patients which were not present in controls [143,144].